[EXAS] Exact Sciences Corporation


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 14.17 Change: 0.79 (5.9%)
Ext. hours: Change: 0 (0%)

chart EXAS

Refresh chart

Strongest Trends Summary For EXAS

EXAS is in the medium-term down -27% below S&P in 1 year. In the long-term up 808% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company?s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cance

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.95% ROE-46.37% ROI-45.3%
Current Ratio17.69 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.06
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities290 K Cash From Investing Activities16.76 M Cash From Operating Activities-34.5 M Gross Profit3.02 M
Net Profit-39.07 M Operating Profit-39.37 M Total Assets253.02 M Total Current Assets223.26 M
Total Current Liabilities18.73 M Total Debt4.83 M Total Liabilities28.18 M Total Revenue8.12 M
Technical Data
High 52 week122.49 Low 52 week56.04 Last close99.74 Last change5.16%
RSI54.16 Average true range3.68 Beta0.78 Volume1.89 M
Simple moving average 20 days4.61% Simple moving average 50 days-7.56% Simple moving average 200 days0.19%
Performance Data
Performance Week10.71% Performance Month-4.47% Performance Quart-14.27% Performance Half4.76%
Performance Year48.38% Performance Year-to-date58.07% Volatility daily2.69% Volatility weekly6.01%
Volatility monthly12.33% Volatility yearly42.7% Relative Volume250.33% Average Volume1.86 M
New High New Low


2020-05-26 06:00:00 | Exact Sciences to participate in June investor conferences

2020-05-17 06:46:00 | Could Exact Sciences Be a Millionaire-Maker Stock?

2020-05-12 15:10:01 | Pivoting From Poop: How Exact Sciences is Turning to OptionĀ #2

2020-05-12 10:23:54 | Is Exact Sciences Stock a Buy?

2020-05-11 10:19:00 | Should Investors Buy the Dip in EXACT Sciences EXAS Stock?

2020-05-07 11:30:47 | Exact Sciences Corp EXAS Q1 2020 Earnings Call Transcript

2020-05-07 10:09:02 | Exact Sciences' EXAS Q1 Earnings Fall Y/Y, Margin Expands

2020-05-07 01:37:54 | Edited Transcript of EXAS earnings conference call or presentation 6-May-20 9:00pm GMT

2020-05-06 20:05:12 | Exact Sciences EXAS Reports Q1 Loss, Tops Revenue Estimates

2020-05-06 15:00:00 | EXACT Sciences Corp. to Host Earnings Call

2020-05-05 10:30:00 | New Model Shared at Digestive Disease Week DDW Demonstrates the Value of CologuardĀ® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

2020-05-05 10:16:02 | Should You Buy Exact Sciences EXAS Ahead of Earnings?

2020-05-05 10:06:02 | Varian VAR Earnings and Revenues Surpass Estimates in Q2

2020-05-05 08:45:12 | Buy 5 Top Stocks Set to Beat Earnings Estimates Tomorrow

2020-05-04 06:00:00 | Exact Sciences to participate in May investor conference

2020-05-03 07:36:00 | 2 Cheap Healthcare Stocks to Buy Now

2020-04-30 10:49:02 | Surmodics SRDX Q2 Earnings and Revenues Beat Estimates

2020-04-29 12:34:04 | Exact Sciences EXAS Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2020-04-22 05:20:40 | Exact Sciences Reports 63% Reduction For Cologuard Testing in April

2020-04-08 17:51:48 | Why 'Kimtirement' is a real thing with this longtime biotech exec

2020-04-08 17:51:48 | Why 'Kimtirement' is a real thing with this longtime biotech exec

2020-04-08 06:00:00 | Exact Sciences schedules first-quarter 2020 earnings call

2020-04-02 09:00:10 | 10x Genomics Appoints Kim Popovits to Board of Directors

2020-04-02 06:00:00 | Exact Sciences Highlights The Opportunity To Seek Screening With CologuardĀ® Through Telehealth

2020-03-26 17:45:09 | Exact Sciences EXAS Stock Sinks As Market Gains: What You Should Know

2020-03-26 13:50:24 | Epic, Exact Sciences among Wisconsin tech firms responding to COVID-19

2020-03-24 09:44:01 | Exact Sciences Grows on New Deals, Down on Coronavirus Scare

2020-03-21 09:22:56 | Is Exact Sciences Corporation's NASDAQ:EXAS CEO Pay Fair?

2020-03-19 06:00:00 | Exact Sciences Takes Action during COVID-19 Pandemic

2020-03-17 17:45:09 | Exact Sciences EXAS Gains But Lags Market: What You Should Know

2020-03-17 15:18:44 | Hedge Funds Have Never Been This Bullish On EXACT Sciences Corporation EXAS

2020-03-12 11:30:03 | Exact Sciences EXAS Down 39.7% Since Last Earnings Report: Can It Rebound?

2020-03-04 07:37:10 | The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

2020-02-27 08:42:01 | Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

2020-02-25 08:28:09 | The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement

2020-02-24 22:39:00 | Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2028

2020-02-24 16:01:00 | Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028

2020-02-19 05:44:10 | Bull of the Day: Guardant Health GH

2020-02-12 22:41:28 | Edited Transcript of EXAS earnings conference call or presentation 11-Feb-20 10:00pm GMT

2020-02-12 15:52:42 | Exact Sciences to acquire more biotech companies; plans to launch liver cancer test in 2020

2020-02-12 09:18:32 | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

2020-02-12 08:56:01 | Exact Sciences EXAS Q4 Earnings and Revenues Rise Y/Y

2020-02-11 18:15:11 | Exact Sciences EXAS Reports Q4 Loss, Tops Revenue Estimates

2020-02-11 17:07:23 | Exact Sciences beats income, revenue projections in 4Q earnings report

2020-02-11 16:05:00 | Exact Sciences Announces Fourth-Quarter 2019 Results

2020-02-11 07:23:06 | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

2020-02-04 18:41:11 | Should Growth Investors Buy this Cancer Screening Biotech Stock?

2020-02-04 12:30:05 | Exact Sciences EXAS Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2020-02-04 11:44:04 | What's in the Cards for Exact Sciences' EXAS Q4 Earnings?

2020-02-03 17:45:10 | Exact Sciences EXAS Outpaces Stock Market Gains: What You Should Know